Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the ...

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

The Food and Drug Administration has asked Moderna for additional data before it will consider approving a combination shot ...

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is ...

A combination messenger RNA vaccine against COVID-19 and seasonal influenza stacked up well against currently recommended vaccines in a phase 3 trial, according to findings published in JAMA.

The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...

Moderna (NASDAQ:MRNA) accelerates cost cuts, trimming 2026 GAAP operating expenses by up to $500 million as COVID-19 vaccine ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...